<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961905</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-2002_BA</org_study_id>
    <nct_id>NCT04961905</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Characteristics and Safety After Administration of NVP-2002</brief_title>
  <official_title>A Phase I Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and Safety After Administration of NVP-2002 and Co-administration of NVP-2002-R1 and NVP-2002-R2 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and&#xD;
      safety after administration of NVP-2002 and co-administration of NVP-2002-R1 and NVP-2002-R2&#xD;
      in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 to evaluate the pharmacokinetic characteristics and safety after administration of&#xD;
      NVP-2002 and co-administration of NVP-2002-R1 and NVP-2002-R2. Which is designed as&#xD;
      ramdomized, oral, single dose, 2×2 crossover.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: Cmax</measure>
    <time_frame>0hours - 72hours</time_frame>
    <description>Cmax of NVP-2002-R1 and NVP-2002-R2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: AUCt</measure>
    <time_frame>0hours - 72hours</time_frame>
    <description>Area under the curve of NVP-2002-R1 and NVP-2002-R2</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single tablet fist, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC fist, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single tablet fist, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC fist, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-2002-R1+NVP-2002-R2</intervention_name>
    <description>NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily</description>
    <arm_group_label>Single tablet fist, fasted</arm_group_label>
    <arm_group_label>Single tablet fist, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-2002</intervention_name>
    <description>NVP-2002 is a combination of NVP-2002-R1 and NVP-2002_R2 NVP-2002, 1 tablet, once daily</description>
    <arm_group_label>FDC fist, fasted</arm_group_label>
    <arm_group_label>FDC fist, fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy adult subjects who signed informed consent&#xD;
&#xD;
          -  Body Mass Index(BMI)=18.5~29.9kg/㎡&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects participated in another clinical trial within 6 months prior to&#xD;
             administration of the study drug&#xD;
&#xD;
          -  Inadequate subject for the clinical trial by the investigator's decision&#xD;
&#xD;
          -  Upper Limits of Normal x 1.5 &lt; Aspartate transaminase(AST), Alanine transminase(ALT),&#xD;
             Total bilirubin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HR LIM</last_name>
    <phone>+82-31-547-9781</phone>
    <email>hrlim@navipharm.co.kr</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

